EPO and dentin dysplasia: In the incident and prevalent DD‐CKD trials, both vadadustat‐treated and darbepoetin‐treated patients maintained their serum EPO levels that were slightly increased at baseline compared with those of patients in the NDD‐CKD trials (20–32 mIU/mL) (Tables 1 and S2).